In a study of patients with FL, LPL, MCL, and marginal zone lymphoma (MZL), treatment with ENTO 800 mg twice daily resulted in response rates ranging from 12% to 35%, with manageable toxicity [11]. The gene discussed is FLT3LG; the disease is marginal zone lymphoma.